Scholarlink

Most patients with thyroid cancers have a promising prognosis. However, certain patients with aggressive thyroid cancers, including radioiodine-refractory differentiated thyroid cancers (RAIR-DTC), poorly differentiated thyroid cancers (PDTC), and anaplastic thyroid cancers (ATC) portend a challenging treatment course. These patients are more likely to fail traditional therapies for thyroid cancer and different therapeutic strategies are needed. Emerging targeted molecular therapies offer a promising new treatment adjunct for this complex clinical problem.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeted Therapies in Conjunction with Surgery for Aggressive Thyroid Cancers

  • 章节

  • 发表日期：

    2025年

查看全文
  • Eileen R. Smith,
  • Taylor C. Brown

摘要

Most patients with thyroid cancers have a promising prognosis. However, certain patients with aggressive thyroid cancers, including radioiodine-refractory differentiated thyroid cancers (RAIR-DTC), poorly differentiated thyroid cancers (PDTC), and anaplastic thyroid cancers (ATC) portend a challenging treatment course. These patients are more likely to fail traditional therapies for thyroid cancer and different therapeutic strategies are needed. Emerging targeted molecular therapies offer a promising new treatment adjunct for this complex clinical problem.